Articles tagged with Heart Failure
A new position statement from CSANZ and ACRA highlights telehealth as a critical tool for increasing access to quality cardiovascular care. The guidance provides best practice guidance for safe use by clinicians while emphasizing patient-centered, culturally inclusive multidisciplinary care.
A recent study published in JAMA Internal Medicine found that oral semaglutide has a potential benefit in reducing heart failure events among people with type 2 diabetes and existing heart failure. The data support the use of oral semaglutide as a treatment option for these patients.
Researchers found that patients seen by cardiologists had lower mortality rates and fewer serious heart problems, including heart attack, sudden failure, or irregular heartbeat. The study suggests close teamwork between surgical and heart teams can improve outcomes after major surgery.
A new study from Uppsala University reveals a substantial increase in cardiomyopathy diagnoses in Sweden between 2004 and 2023, associated with high excess mortality rates. The study highlights the need for improved detection and targeted treatments to address this growing public health concern.
Researchers have developed a non-invasive method to estimate blood oxygen levels in heart failure patients using standard cardiac MRI. This breakthrough could spare thousands from undergoing risky tube procedures, allowing for safer and more frequent monitoring.
A recent study from Penn State College of Medicine researchers found that helper T cells, typically involved in fighting infections, become overly activated in failing human hearts, causing damage. The activation of these T cells highlights the impact of inflammation and immune dysfunction in heart failure.
Researchers at University of California San Diego discover gene therapy restoring connexin-43 improves heart function and extends survival in several forms of arrhythmogenic cardiomyopathy. The approach may have broader therapeutic potential across multiple genetic forms of the disease, addressing a critical unmet need.
Researchers identify circulating extracellular vesicles produced in diseased kidneys as the culprit behind toxicity in the heart. The discovery could lead to the development of a blood test to identify patients at high risk for serious heart problems and novel treatments to prevent and treat heart failure.
Researchers have shown that human hearts can regrow muscle cells after a heart attack, paving the way for new treatments to reverse heart failure. The discovery was made possible by pioneering techniques that use living tissue samples taken from patients during bypass surgery.
Researchers discovered that inhibiting a protein called RBM20 can improve heart filling and flexibility in mice with heart failure. The study also found positive impacts on energy metabolism, mitochondrial function, antioxidant balance, and blood flow.
A study of 800+ US hospitals and 700,000 patients reveals disparities in care among Asian American subgroups. Filipino and Vietnamese patients are least likely to receive guideline-recommended heart failure care.
Adults born with heart defects are at increased risk of cardiac complications as they age. The new guideline provides recommendations for monitoring, counseling, and treating Congenital Heart Disease (CHD), including mental health assessment and physical activity guidance. It also emphasizes the importance of access to ongoing speciali...
A $25M study will enroll 18,000 adults at high risk of heart disease and track their progress using smartphone fitness trackers. The trial aims to prove that increasing physical activity can prevent heart attacks and strokes.
A new study found that calcium accumulation in breast arteries and its progression on mammograms can predict future cardiovascular disease. Women with more severe calcification and those whose calcification worsened over time had a higher risk of heart-related events, such as heart attack, stroke, and death.
Researchers at SwRI and Trinity University are working on a new prodrug to mitigate ischemia/reperfusion injury (IRI), which causes permanent cellular and tissue damage. The team aims to protect against IRI by targeting protein misfolding during cellular stress.
Researchers at Penn State are developing a small, durable ventricular assist device (VAD) specifically designed for young children with heart failure. The PSU Child VAD aims to provide long-term support while waiting for a heart transplant, improving quality of life and outcomes.
Researchers at the University of Maryland School of Medicine have identified a bacterial enzyme called zmpB that can cause fatal heart complications in people infected with pneumonia. The enzyme potentiates the invasion of Streptococcus pneumoniae into the heart, leading to damage and potentially life-threatening outcomes.
Recent trials have shown that catheter-based procedures can match the long-term results of open-heart surgery in relatively healthy patients with valvular disease. These procedures offer life-saving options to people too frail for open-heart surgery and are expected to bring more upcoming trials to New Brunswick.
A recent study published in the American Journal of Preventive Cardiology found that only 13% of US adults with cardiovascular disease met optimal LDL-C management, highlighting significant gaps between guideline recommendations and clinical care. The study suggests actionable steps to improve adherence, including increased use of non-...
A large study found that people with type 1 and type 2 diabetes have a higher risk of sudden cardiac death, particularly in younger adults. The research also showed that sudden cardiac death contributes to shorter life expectancy for those with diabetes.
Researchers tracked 120 older veterans taking gabapentinoids and loop diuretics, finding that only 4 doctors correctly identified the gabapentinoids as the cause of leg swelling. The study highlights the dangers of 'prescribing cascades' and emphasizes the need for regular monitoring and alternative treatment options.
A mouse study by University of California, Riverside scientists suggests microplastic exposure may accelerate the development of atherosclerosis in males. The study found microplastics dramatically worsened plaque buildup in male mice, but not females.
A new online calculator uses percentiles to help younger adults forecast their risk of a heart event over the next 30 years. The tool calculates a person's 30-year risk of developing heart disease using common health measures, such as blood pressure and cholesterol.
A Cochrane review found that low-dose colchicine reduced heart attacks and strokes in people with a history of heart disease or stroke. The study involved nearly 23,000 participants and showed that taking colchicine could prevent about two of each heart attack and stroke among those with cardiovascular disease.
A new genetic risk score combines rare and common gene variants with non-coding genome information to predict arrhythmia risk. This comprehensive framework can be applied to other genetically influenced diseases like cancer and Parkinson's Disease.
A new study found that standard medical care, including blood thinners, is the better choice for older people with irregular heart rhythms who are at high risk of stroke and bleeding. The catheter-based procedure was non-inferior to medical therapy in reducing stroke risk but caused more bleeding in higher-risk patients.
Researchers found that an earlier blood transfusion may reduce the risk of heart failure and irregular heartbeat in adults with heart disease. The study suggests that waiting until hemoglobin levels are low before transfusing blood may not be the best strategy for high-risk patients.
A new study reveals that a large gap between two common kidney function tests may indicate future disease, particularly among older adults. The research found that over a third of hospitalized participants had a significant difference in their creatinine and cystatin C readings, which can predict serious health problems.
A comprehensive analysis of 70,000 participants across 10 trials found that SGLT2 inhibitors reduced the risk of chronic kidney disease (CKD) progression by 38% and slowed eGFR decline by 51%. The treatment was beneficial for all levels of kidney function and albuminuria levels, particularly in reducing hospitalizations.
The study suggests that SGLT2 inhibitors can benefit patients with varying levels of kidney function and albuminuria. Routine use of these medications may lead to improved kidney outcomes across different patient groups.
The new approach uses lab-grown heart tissue made from reprogrammed adult stem cells, delivered through a tiny incision. In preclinical testing, the stem cell patch restored heart function and improved healing, offering a new way to repair damaged hearts.
A study found that long-term use of melatonin supplements may increase the risk of heart failure, hospitalization, and death in adults with chronic insomnia. The research analyzed data from a large international database and found consistent and significant increases in serious health outcomes, even after balancing for other risk factors.
Cardiac rehabilitation significantly improves short and long-term recovery for heart surgery patients, but women participate less than men due to barriers such as lower referral rates, clinician bias, and caregiving responsibilities. The American Heart Association scientific statement calls for targeted interventions to improve enrollm...
The Lehigh University team created a computational model to predict the hemodynamic response of patients with AFib, helping tailor neurostimulation dosages. The model validated against clinical data and predicted accurate effects on blood pressure, heart rate, and stroke volume.
Patients with weak heart function who receive stem cell therapy shortly after a heart attack have lower rates of heart failure and hospital stays. The technique may be a valuable add-on procedure for patients with weakened heart function after a heart attack to prevent subsequent heart failure.
Researchers discovered that cardiac fibroblasts use a signaling pathway to promote harmful changes in the heart, weakening its ability to pump blood efficiently. Blocking this pathway in mice models improved heart function, suggesting that fibroblasts could be a potential target for new therapeutic strategies.
Researchers validate GLIS model as a reliable predictor of sarcopenia and mortality risk in older patients with heart failure, outperforming existing tests. The model's accuracy enables early detection of physical decline and poor prognosis, informing treatment planning and discharge decisions.
A study found that the Clinical Frailty Scale (CFS) is a quick predictor of patient risk after heart failure administration. The researchers used anonymized patient information from Japan and found that CFS scores were strongly correlated with physical and cognitive impairment, as well as increased mortality risk.
A new study published in TCT 2025 reveals that at least 4.7 million people aged 65-85 living in the US have moderate or greater valvular heart disease (VHD), and at least 10.6 million have clinically significant VHD. The prevalence of VHD increases with advanced age, highlighting the need for screening and treatment programs.
The merger strengthens CRF's leadership in medtech, integrating Fogarty's expertise in early-stage innovation. The unified platform will accelerate breakthroughs into patient care, driving global progress in cardiovascular medicine.
A new sirolimus-eluting balloon has been shown to be noninferior to traditional treatments for in-stent restenosis. The study, presented at TCT 2025, found the balloon to be safe and effective for treating ISR without adding extra layers of stents.
A study found that super-high-pressure non-compliant balloons (NCB) are non-inferior to IVL balloon catheters for lesion preparation and stent expansion in severely calcified lesions. The results showed similar safety profiles and efficacy across various patient subgroups.
A study found that longer accumulations of steps in one go have a greater health benefit than short bouts spread out across the day. Walking continuously for 10-15 minutes per day was associated with lower risk of cardiovascular events and mortality.
The Cardiovascular Research Foundation (CRF) has announced the 2025 SET-10 Rankings, honoring institutions whose groundbreaking research is shaping the future of cardiovascular care. The rankings recognize academic and medical institutions that are advancing the science and improving patient outcomes.
A new study published in The Lancet found that semaglutide, a 'weight loss' drug, can help prevent heart attacks and other major cardiac events, regardless of the amount of weight people lose. The study suggests there are multiple ways the drug benefits the heart, beyond its protective effect on cardiovascular health.
A recent study published in the European Heart Journal found that female bodybuilders are at a high risk of sudden cardiac death, with a mortality rate 20 times higher than amateur athletes. The study also revealed a significant proportion of deaths from suicide and homicide.
A potential new drug called RBM20-ASO has been shown to improve cardiac function in a mouse model of heart failure with preserved ejection fraction (HFpEF). The therapy reduces left ventricular stiffness and abnormal thickening of the heart muscle, even in the presence of comorbidities.
This study found that GLP-1RAs and SGLT2is offer the greatest cardiovascular benefits for adults with type 2 diabetes. The magnitude of benefit depends on baseline age, atherosclerotic cardiovascular disease, heart failure, and kidney impairment.
A new scientific statement from the American Heart Association details differences in cardiac rehabilitation access, participation, and outcomes for women compared to men. The statement suggests evidence-based strategies to increase referral and completion rates for cardiac rehab programs among women with cardiovascular disease.
The American College of Cardiology has launched a new education program to educate clinicians on the latest advances in heart failure management and treatment. The program aims to improve outcomes among patients with heart failure by providing education on tailored treatments for different subtypes of HF.
A phase 3 clinical trial found that sotatercept significantly reduces the likelihood of worsening disease in patients with severe pulmonary hypertension when added to standard treatment within the first year after diagnosis. The medication reduced the risk of deterioration by 76% and hospitalizations by nearly half.
The American College of Cardiology has released a scientific statement on inflammation and its connection to various cardiovascular diseases, including coronary artery disease and heart failure. The statement confirms years of research confirming the importance of inflammation as an underlying contributor to CVDs.
A large-scale study analyzing health records for over 9 million adults in South Korea and nearly 7,000 people in the U.S. found that more than 99% had at least one risk factor before their first cardiac event. High blood pressure was the most common culprit, affecting over 95% of patients.
A multidisciplinary panel published in the Journal of Pediatrics advocates for accelerated diagnosis of familial hypercholesterolemia, a life-threatening genetic condition. Universal lipid screening is recommended to identify affected children at high risk of heart disease decades earlier than those without the condition.
The TCT AI Lab equips clinicians with skills to integrate AI into clinical practice, advancing precision, efficiency, and patient outcomes. The initiative is made possible by a generous grant from the Jon DeHaan Foundation.
A novel drug target, CD300a, has been identified to suppress immune cell activation and prevent chronic heart and kidney failure after acute tissue injury. The treatment preserves cardiac function and reduces renal fibrosis in mice with genetic deficiency of CD300a.
A study published in Annals of Translational Medicine found that intense light therapy can lower troponin levels and increase ANGPTL4 protein, protecting heart tissue. The treatment may reduce the risk of myocardial injuries after non-cardiac surgery, which affects 20% of patients and increases one-year mortality rates.
A new study published in JAMA Network Open found that older adults living in flood-hit areas in New Jersey faced a 5% higher risk of heart disease for up to five years after Hurricane Sandy's landfall. Flooded ZIP code areas had lower median incomes and higher area deprivation index scores, which are linked to worse health outcomes.
Researchers found that diabetes directly affects the heart's structure and energy production in humans for the first time. Diabetes causes distinct molecular changes to heart cells and structural changes to the muscle, particularly in patients with ischaemic cardiomyopathy.
A study by Northwestern University found that Black adults are hospitalized for heart failure at age 60.1, while white adults are hospitalized at age 73.6. The gap is largely attributed to differences in insurance, unemployment, and education levels.